These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8601568)

  • 21. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas.
    Kaufmann O; Fietze E; Mengs J; Dietel M
    Am J Clin Pathol; 2001 Dec; 116(6):823-30. PubMed ID: 11764070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synchronous diffuse malignant mesothelioma and carcinomas in asbestos-exposed individuals.
    Attanoos RL; Thomas DH; Gibbs AR
    Histopathology; 2003 Oct; 43(4):387-92. PubMed ID: 14511258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Undifferentiated carcinoma of cervical node metastases in patients with an unknown primary lesion: an immunohistochemical study].
    Nakamizo M; Kamata SE; Kawabata K; Takahashi H; Nigauri T; Hoki K; Yanagisawa A
    Nihon Jibiinkoka Gakkai Kaiho; 1994 Dec; 97(12):2202-7. PubMed ID: 7861291
    [TBL] [Abstract][Full Text] [Related]  

  • 24. THE IMPORTANCE OF IMMUNOHISTOCHEMICAL STUDIES IN THE DIAGNOSIS OF CANCER OF UNKNOWN PRIMARY ORIGIN.
    Beisenayeva A; Cialkowska-Rysz A; Zhumaliyeva V; Omarova I; Kabildina N; Sirota V
    Georgian Med News; 2015 Dec; (249):73-80. PubMed ID: 26719554
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of Epstein-Barr virus infection in sinonasal small round cell tumors.
    Shinokuma A; Hirakawa N; Tamiya S; Oda Y; Komiyama S; Tsuneyoshi M
    J Cancer Res Clin Oncol; 2000 Jan; 126(1):12-8. PubMed ID: 10641744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunohistochemical distinction between primary adenocarcinoma of the bladder and secondary colorectal adenocarcinoma.
    Wang HL; Lu DW; Yerian LM; Alsikafi N; Steinberg G; Hart J; Yang XJ
    Am J Surg Pathol; 2001 Nov; 25(11):1380-7. PubMed ID: 11684954
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Metastatic cancers of unknown primary site].
    Krulik M
    Presse Med; 1996 Nov; 25(35):1754-8. PubMed ID: 8977590
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Diagnostic value of bone marrow biopsy for bone marrow metastatic tumor with unknown primary tumor site].
    Wu Y; Yao LQ; Cheng J; Tian H
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 May; 30(5):1069-71. PubMed ID: 20501396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Metastatic carcinoma of unknown origin].
    Fizazi K; Culine S
    Bull Cancer; 1998 Jul; 85(7):609-17. PubMed ID: 9752267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Utility of Sox10 labeling in metastatic breast carcinomas.
    Nelson ER; Sharma R; Argani P; Cimino-Mathews A
    Hum Pathol; 2017 Sep; 67():205-210. PubMed ID: 28843711
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of HNF-1β in cervical carcinomas: an immunohistochemical study of 155 cases.
    Němejcová K; Cibula D; Dundr P
    Diagn Pathol; 2015 Mar; 10():8. PubMed ID: 25884453
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnosis and management of metastatic neoplasms with unknown primary.
    Bochtler T; Löffler H; Krämer A
    Semin Diagn Pathol; 2018 May; 35(3):199-206. PubMed ID: 29203116
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The management of patients with adenocarcinoma and poorly differentiated carcinoma of unknown primary site.
    Greco FA; Hainsworth JD
    Semin Oncol; 1989 Aug; 16(4 Suppl 6):116-22. PubMed ID: 2669133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Steroid hormone receptors in mammary carcinoma. Immunohistochemical detection and prognostic significance].
    Reiner A; Neumeister B; Reiner G; Jakesz R; Kolb R; Schemper M; Spona J
    Zentralbl Pathol; 1991; 137(3):233-41. PubMed ID: 1657132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metastatic thoracic lymph node carcinoma of unknown origin on which we performed two kinds of immunohistochemical examinations.
    Yoshino N; Yamauchi S; Hino M; Ohaki Y; Koizumi K; Shimizu K
    Ann Thorac Cardiovasc Surg; 2006 Aug; 12(4):283-6. PubMed ID: 16977301
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site.
    van der Gaast A; Verweij J; Planting AS; Hop WC; Stoter G
    J Clin Oncol; 1995 Jul; 13(7):1720-5. PubMed ID: 7541451
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The prognostic application of cytokeratin typing of nonsmall cell lung carcinoma. A retrospective study.
    Cohen R; Guber A; Siegal A; Bruderman I; Huszar M; Yellin A; Marom Z; Geiger B
    Cancer; 1997 Feb; 79(3):468-73. PubMed ID: 9028356
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs).
    Pisacane A; Cascardi E; Berrino E; Polidori A; Sarotto I; Casorzo L; Panero M; Boccaccio C; Verginelli F; Benvenuti S; Dellino M; Comoglio P; Montemurro F; Geuna E; Marchiò C; Sapino A
    Virchows Arch; 2023 Mar; 482(3):463-475. PubMed ID: 36346458
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adenocarcinoma in females detected in serous effusions. Cytomorphologic aspects and immunocytochemical reactivity to cytokeratins 7 and 20.
    Longatto Filho A; Bisi H; Alves VA; Kanamura CT; Oyafuso MS; Bortolan J; Lombardo V
    Acta Cytol; 1997; 41(4):961-71. PubMed ID: 9250286
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cancers of unknown origin: 311 cases].
    Lortholary A; Abadie-Lacourtoisie S; Guérin O; Mege M; Rauglaudre GD; Gamelin E
    Bull Cancer; 2001 Jun; 88(6):619-27. PubMed ID: 11459709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.